ArticleMolecular biology reports2025
Investigation of the effects of gabapentin on high glucose-induced neurotoxicity and genotoxicity in an in vitro model of diabetic neuropathy and in silico molecular docking analysis.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGabapentin is the pharmacologic treatment of choice for symptom relief in diabetic neuropathy. However, its effect on high glucose (HG)-induced neurotoxicity and genotoxicity under diabetic neuropathy conditions remains unclear. The aim of this study was to investigate the effects of gabapentin on cytogenotoxicity in HG-induced neuropathy in dorsal root ganglion (DRG) neurons.
methodsDRG neurons were isolated from neonatal Sprague-Dawley rats (n = 10). After treatment of these neurons with HG (45 mmol/L) and gabapentin (1,10, 100, and 1000 µM), cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2 H-tetrazolium bromide (MTT) assay. Furthermore, the effects on DNA damage in DRG neurons exposed to HG (45 mmol/L) and gabapentin (10 and 100 µM) were investigated by comet assay.
resultsWhen HG + Gabapentin (1 µM), HG + Gabapentin (10 µM), HG + Gabapentin (100 µM), and HG + Gabapentin (1000 µM) groups were compared with the HG group, no statistically significant change in cell viability was determined (p > 0.05). HG + Gabapentin (10 µM) and HG + Gabapentin (100 µM) groups were not statistically significant in genotoxicity compared to HG group (p > 0.05).
conclusionsOur results suggest that gabapentin does not modulate HG-induced cytogenotoxicity in HG-exposed DRG neurons. Our findings, which emphasize the safety of gabapentin in diabetic neuropathy, need more detailed studies. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
40748554What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.